MOLECULAR PARTNERS AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.315 CHF | +2.47% |
|
-1.04% | -3.63% |
Presenter SpeechDavid Lebowitz (Analysts)Hello, and welcome again to the Morgan Stanley 18th A...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Molecular Partners AG is a Switzerland-based clinical-stage biotech company developing DARPin (Designed Ankyrin Repeat Proteins) a new class of custom-built protein therapeutics based on natural binding proteins that open a new dimension of multi-functionality and multi-target specificity in drug design. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
3.315
CHF
Average target price
9.35
CHF
Spread / Average Target
+182.05%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -3.63% | 118M | |
| +5.66% | 109B | |
| +11.23% | 105B | |
| -0.38% | 22.25B | |
| -12.15% | 22.09B | |
| -7.66% | 18.68B | |
| -36.52% | 17.58B | |
| -10.09% | 16.85B | |
| +3.33% | 13.76B | |
| +36.58% | 12.46B |
- Stock Market
- Equities
- MOLN Stock
- News Molecular Partners AG
- Transcript : Molecular Partners AG Presents at Morgan Stanley 18th Annual Global Healthcare Conference, Sep-16-2020 01